Abbott’s FDA Approval Revolutionizes Treatment for Peripheral Vascular Disease with Esprit™ BTK System

Abbott Laboratories has made a significant breakthrough in the treatment of chronic limb-threatening ischemia (CLTI) with its recent FDA approval of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System. This innovation marks a pivotal moment in the management of peripheral vascular diseases, particularly those affecting arteries below the knee (BTK). The Breakthrough Esprit BTK System […] The post Abbott’s FDA Approval Revolutionizes Treatment for Peripheral Vascular Disease with Esprit™ BTK System appeared first on iData Research.